# Development of gold nanoparticles stabilized by PLGA and PVA for application in photothermal therapy

**Authors:** Soraia Borges, Natanael Fernandes, André F. Moreira

PMC · DOI: 10.3389/fcell.2026.1759401 · Frontiers in Cell and Developmental Biology · 2026-02-05

## TL;DR

Researchers developed gold nanoparticles stabilized by PLGA and PVA for potential use in cancer photothermal therapy, showing promising results in temperature increase and cell compatibility.

## Contribution

The study introduces a novel method for producing PLGA-gold nanomaterials with distinct structural arrangements and evaluates their photothermal and cytocompatible properties.

## Key findings

- Formulation A and B produced nanoparticles with similar size and charge but differing structural arrangements of gold spheres.
- Formulation A showed a higher temperature increase (21°C) compared to B (13.9°C) under NIR laser irradiation.
- Both formulations demonstrated high cell viability (≈100%) in FibH and HeLa cells, indicating good cytocompatibility.

## Abstract

In today's world, cancer remains a major public health problem. Consequently, there has been a focused investigation of alternative therapeutic approaches to address this ongoing health concern. In this study, PLGA-gold nanomaterials were produced through various processes to determine whether these variations affected their structural integrity and, consequently, their physicochemical properties.

The PLGA-gold nanomaterials were produced through an oil-in-water (O/W) process (Formulation A) or a water-in-oil-in-water (W1/O/W2) process (Formulation B). The nanomaterials' physiscochemical properties were characterized by electron microscopy, dynamic light scattering, and UV-vis. Photothermal studies were performed using a 808 nm NIR laser and the PLGA-gold nanomaterials cytocompatibility was evaluated using resazurin.

Both methods originated particles with similar size and charge, 276.8 and –19.6 mV for formulation A and 317.5 nm and –18.6 mV for formulation B. Nevertheless, the TEM images revealed structural differences, with formulation A presenting the gold spheres clustered in the particle nucleus, whereas in formulation B the gold spheres were found in the outer PLGA shell. Moreover, upon irradiation with a NIR laser (808 nm, 1.7 W cm–2, 10 min), the particles showed a concentration dependent photothermal effect, promoting a temperature increase of 21 °C and 13.9 °C for formulation A and B at 400 μg/mL, respectively. Additionally, preliminary cellular assays demonstrated that the PLGA-gold nanoparticles are cytocompatible, with both FibH and HeLa cells exhibiting a cellular viability of approximately 100%.

Thus, these results underline the potential the PLGA-gold nanoparticles, particularly formulation A, for advanced applications in nanomedicine. In the future the encapsulation of drugs will be evaluated in order to characterise both the uptake and the cytotoxic capacity of this multifunctional nanomaterial. Additionally, the utilization of more complex in vitro models, such as tumor spheroids and animal models, will then be essential to determine the therapeutic potential of PLGA/gold nanoparticles.

## Linked entities

- **Chemicals:** PLGA (PubChem CID 36797), PVA (PubChem CID 11199), doxorubicin (PubChem CID 31703)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** Cancer (MESH:D009369), hyperthermia (MESH:D005334), cytotoxic (MESH:D064420), negroid cervix (MESH:D002577), death (MESH:D003643)
- **Chemicals:** polymer (MESH:D011108), PVA (MESH:C063253), ester (MESH:D004952), HAuCl4 (MESH:C024568), dichloromethane (MESH:D008752), O (MESH:D010100), glycolic acid (MESH:C031149), Gold (MESH:D006046), Tri-sodium citrate (MESH:C514290), metal (MESH:D008670), EtOH (MESH:D000431), silver (MESH:D012834), Water (MESH:D014867), Oil (MESH:D009821), resorufin (MESH:C014180), Polyvinyl Alcohol (MESH:D011142), K+ (MESH:D011188), aluminium (MESH:D000535), AgNPs (-), glucose (MESH:D005947), hydrogen (MESH:D006859), PLGA (MESH:D000077182), W (MESH:D014414), CO2 (MESH:D002245), resazurin (MESH:C005843)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** Q150R, C at 400, C at 200
- **Cell lines:** CCL-2TM — Mus musculus (Mouse), Undefined cell line type (CVCL_M023), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916575/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12916575/full.md

## References

64 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916575/full.md

---
Source: https://tomesphere.com/paper/PMC12916575